Retinopathy of Prematurity clinical trials at UCSF

2 in progress, 1 open to eligible people

Showing trials for

  • Bevacizumab Treatment For Posterior Zone I ROP

    open to eligible people ages up to 6 months

    Type 1 retinopathy of prematurity in zone I represents the most severe type of ROP and has the worst prognosis. It is unknown whether low-dose bevacizumab will be successful in these severe cases. Also unknown is the timing and extent of peripheral retinal vascularization after low-dose bevacizumab compared with the standard dose. The current study will evaluate whether doses of 0.063 mg and 0.25mg are effective as treatment for type 1 ROP, with ROP and retinal vessels all in zone I.

    San Francisco, California and other locations

  • Low-Dose Bevacizumab vs Laser for Type 1 ROP

    Sorry, in progress, not accepting new patients

    This randomized clinical trial will compare retinal outcomes with low-dose intravitreous bevacizumab (0.063 mg) versus laser photocoagulation as treatment for infants with type 1 retinopathy of prematurity (ROP). The study also will assess neurodevelopment, refractive error, visual acuity, and peripheral visual fields.

    San Francisco, California and other locations

Last updated: